Thank you.
I want to thank all the witnesses and I want to thank Ms. Goodridge for bringing this study into a priority lineup. It is an extremely important study and very timely.
Dr. Gordon, you're a very compelling witness, I have to say.
Most of my five minutes will be probably devoted to just drilling down on a few issues.
Can you talk to me about interval cancers and their relative importance?
Having been versed in this over many years, you might say that the traditional thinking is that aggressive cancers do not lend themselves to screening because almost by definition they appear between screening intervals and often the younger the woman, the more aggressive the cancer. This applies to other types of cancers of course, which is maybe one of the limitations of screening.
Maybe you could clarify what you think of that based on what we know today, especially with the technology that we have today.
Is this becoming a more outdated phenomenon?